Cargando…
Safety and efficacy of doxorubicin-eluting superabsorbent polymer microspheres for the treatment of liver metastases from neuroendocrine tumours: preliminary results
BACKGROUND: The aim of the study was to retrospectively evaluate the symptom control, tumour response, and complication rate in patients with liver-predominant metastatic neuroendocrine tumours treated with transarterial chemoembolization using doxorubicin-eluting superabsorbent polymer (SAP) micros...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
De Gruyter
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5330173/ https://www.ncbi.nlm.nih.gov/pubmed/28265235 http://dx.doi.org/10.1515/raon-2017-0007 |
_version_ | 1782511210104619008 |
---|---|
author | Bonne, Lawrence Verslype, Chris Laenen, Annouschka Cornelissen, Sandra Deroose, Christophe M. Prenen, Hans Vandecaveye, Vincent Van Cutsem, Eric Maleux, Geert |
author_facet | Bonne, Lawrence Verslype, Chris Laenen, Annouschka Cornelissen, Sandra Deroose, Christophe M. Prenen, Hans Vandecaveye, Vincent Van Cutsem, Eric Maleux, Geert |
author_sort | Bonne, Lawrence |
collection | PubMed |
description | BACKGROUND: The aim of the study was to retrospectively evaluate the symptom control, tumour response, and complication rate in patients with liver-predominant metastatic neuroendocrine tumours treated with transarterial chemoembolization using doxorubicin-eluting superabsorbent polymer (SAP) microspheres. PATIENTS AND METHODS: Patients with neuroendocrine liver metastases who underwent hepatic transarterial chemoembolization using doxorubicin-eluting SAP-microspheres (50–100 μm Hepasphere/Quadrasphere Microsphere® particles, Merit Medical, South Jordan, Utah, USA) were included in this study. Pre-and post-procedure imaging studies were evaluated to assess short and intermediate-term tumour response using modified RECIST criteria. Symptom relief and procedure-related complications were evaluated. RESULTS: A total of 27 embolization procedures were performed on 17 patients. Twelve of 17 patients (70%) were symptomatic, including carcinoid syndrome (n = 8) and severe, uncontrollable hypoglycemia (n = 4). Eight of 12 patients (67%) had complete symptom relief, and the remaining 4 (33%) had partial relief. One patient developed ischemic cholecystitis (6%). No other hepatobiliary complications occurred. Short-term and intermediate-term imaging follow-up was available for 15/17 patients (88%) and 12/14 patients (86%) respectively. At short-term follow-up (< 3 months), 14 patients (93%) showed partial response and the remaining patient had progressive disease (7%). At intermediate-term imaging follow-up (> 3 months), partial response, stable disease and progressive disease were found respectively in 7 (58%), 3 (25%) and 2 (17%) patients. CONCLUSIONS: Chemoembolization with doxorubicin-eluting SAP-microspheres is a safe and effective treatment option for neuroendocrine liver metastases and is associated with a low complication rate. In particular, no clinically evident liver necrosis or bile duct complications were encountered. |
format | Online Article Text |
id | pubmed-5330173 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | De Gruyter |
record_format | MEDLINE/PubMed |
spelling | pubmed-53301732017-03-07 Safety and efficacy of doxorubicin-eluting superabsorbent polymer microspheres for the treatment of liver metastases from neuroendocrine tumours: preliminary results Bonne, Lawrence Verslype, Chris Laenen, Annouschka Cornelissen, Sandra Deroose, Christophe M. Prenen, Hans Vandecaveye, Vincent Van Cutsem, Eric Maleux, Geert Radiol Oncol Research Article BACKGROUND: The aim of the study was to retrospectively evaluate the symptom control, tumour response, and complication rate in patients with liver-predominant metastatic neuroendocrine tumours treated with transarterial chemoembolization using doxorubicin-eluting superabsorbent polymer (SAP) microspheres. PATIENTS AND METHODS: Patients with neuroendocrine liver metastases who underwent hepatic transarterial chemoembolization using doxorubicin-eluting SAP-microspheres (50–100 μm Hepasphere/Quadrasphere Microsphere® particles, Merit Medical, South Jordan, Utah, USA) were included in this study. Pre-and post-procedure imaging studies were evaluated to assess short and intermediate-term tumour response using modified RECIST criteria. Symptom relief and procedure-related complications were evaluated. RESULTS: A total of 27 embolization procedures were performed on 17 patients. Twelve of 17 patients (70%) were symptomatic, including carcinoid syndrome (n = 8) and severe, uncontrollable hypoglycemia (n = 4). Eight of 12 patients (67%) had complete symptom relief, and the remaining 4 (33%) had partial relief. One patient developed ischemic cholecystitis (6%). No other hepatobiliary complications occurred. Short-term and intermediate-term imaging follow-up was available for 15/17 patients (88%) and 12/14 patients (86%) respectively. At short-term follow-up (< 3 months), 14 patients (93%) showed partial response and the remaining patient had progressive disease (7%). At intermediate-term imaging follow-up (> 3 months), partial response, stable disease and progressive disease were found respectively in 7 (58%), 3 (25%) and 2 (17%) patients. CONCLUSIONS: Chemoembolization with doxorubicin-eluting SAP-microspheres is a safe and effective treatment option for neuroendocrine liver metastases and is associated with a low complication rate. In particular, no clinically evident liver necrosis or bile duct complications were encountered. De Gruyter 2017-02-22 /pmc/articles/PMC5330173/ /pubmed/28265235 http://dx.doi.org/10.1515/raon-2017-0007 Text en © 2017 Radiol Oncol |
spellingShingle | Research Article Bonne, Lawrence Verslype, Chris Laenen, Annouschka Cornelissen, Sandra Deroose, Christophe M. Prenen, Hans Vandecaveye, Vincent Van Cutsem, Eric Maleux, Geert Safety and efficacy of doxorubicin-eluting superabsorbent polymer microspheres for the treatment of liver metastases from neuroendocrine tumours: preliminary results |
title | Safety and efficacy of doxorubicin-eluting superabsorbent polymer microspheres for the treatment of liver metastases from neuroendocrine tumours: preliminary results |
title_full | Safety and efficacy of doxorubicin-eluting superabsorbent polymer microspheres for the treatment of liver metastases from neuroendocrine tumours: preliminary results |
title_fullStr | Safety and efficacy of doxorubicin-eluting superabsorbent polymer microspheres for the treatment of liver metastases from neuroendocrine tumours: preliminary results |
title_full_unstemmed | Safety and efficacy of doxorubicin-eluting superabsorbent polymer microspheres for the treatment of liver metastases from neuroendocrine tumours: preliminary results |
title_short | Safety and efficacy of doxorubicin-eluting superabsorbent polymer microspheres for the treatment of liver metastases from neuroendocrine tumours: preliminary results |
title_sort | safety and efficacy of doxorubicin-eluting superabsorbent polymer microspheres for the treatment of liver metastases from neuroendocrine tumours: preliminary results |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5330173/ https://www.ncbi.nlm.nih.gov/pubmed/28265235 http://dx.doi.org/10.1515/raon-2017-0007 |
work_keys_str_mv | AT bonnelawrence safetyandefficacyofdoxorubicinelutingsuperabsorbentpolymermicrospheresforthetreatmentoflivermetastasesfromneuroendocrinetumourspreliminaryresults AT verslypechris safetyandefficacyofdoxorubicinelutingsuperabsorbentpolymermicrospheresforthetreatmentoflivermetastasesfromneuroendocrinetumourspreliminaryresults AT laenenannouschka safetyandefficacyofdoxorubicinelutingsuperabsorbentpolymermicrospheresforthetreatmentoflivermetastasesfromneuroendocrinetumourspreliminaryresults AT cornelissensandra safetyandefficacyofdoxorubicinelutingsuperabsorbentpolymermicrospheresforthetreatmentoflivermetastasesfromneuroendocrinetumourspreliminaryresults AT deroosechristophem safetyandefficacyofdoxorubicinelutingsuperabsorbentpolymermicrospheresforthetreatmentoflivermetastasesfromneuroendocrinetumourspreliminaryresults AT prenenhans safetyandefficacyofdoxorubicinelutingsuperabsorbentpolymermicrospheresforthetreatmentoflivermetastasesfromneuroendocrinetumourspreliminaryresults AT vandecaveyevincent safetyandefficacyofdoxorubicinelutingsuperabsorbentpolymermicrospheresforthetreatmentoflivermetastasesfromneuroendocrinetumourspreliminaryresults AT vancutsemeric safetyandefficacyofdoxorubicinelutingsuperabsorbentpolymermicrospheresforthetreatmentoflivermetastasesfromneuroendocrinetumourspreliminaryresults AT maleuxgeert safetyandefficacyofdoxorubicinelutingsuperabsorbentpolymermicrospheresforthetreatmentoflivermetastasesfromneuroendocrinetumourspreliminaryresults |